Quick answer
Why is "CJC-1295" ambiguous, and how can a laboratory confirm which form it has? In the original 2005 paper CJC-1295 named a specific molecule: a tetrasubstituted hGRF(1-29) carrying a C-terminal lysine with a maleimidopropionamide linker, designed to bind albumin (the DAC form). The unlinked backbone is sold as "CJC-1295 without DAC" or modified GRF(1-29). They differ in mass, in persistence and in assay behavior, so a certificate of analysis should state the sequence, the linker status and an intact mass. This article explains the naming, the checks that tell the forms apart and the questions to ask of documentation. V8 supplies the no-DAC form. For laboratory research use only.
Two vials can carry the same short name and contain different molecules. That is the situation with CJC-1295, and it is the single most useful thing to know before reading the literature or ordering a reagent. This article is an identity guide rather than a mechanism review: it explains how the name came about, what separates the with-DAC and no-DAC forms chemically, which analytical results confirm a form, and what a careful reader should ask of a certificate. It is for laboratory research only; not for human or animal consumption.
How the name arose
The 2005 paper that introduced the compound described three maleimido derivatives of hGRF(1-29) bioconjugated to human serum albumin ex vivo, and identified the best of them, CJC-1295, as a tetrasubstituted form of hGRF(1-29) with an added N-epsilon-3-maleimidopropionamide derivative of lysine at the C-terminus (Jetté and colleagues, 2005). In that usage the name refers to the whole designed molecule, backbone and linker together. The "no DAC" label came later and refers to the backbone without the albumin-reactive group; the story of why the stabilized backbone existed independently is in the history of the GHRH fragment and in the CJC-1295 (No DAC) research guide, which refers to the same sequence as modified GRF(1-29). As a result, "CJC-1295" in a paper title or a product listing can mean either form, and the only safe reading is to look for an explicit statement of linker status.
| Label | Backbone | Albumin-reactive linker | Persistence property |
|---|---|---|---|
| Native GHRH(1-44) | 44 residues, native sequence | No | Intact peptide half-life of minutes in plasma (Frohman et al., 1986) |
| GHRH(1-29)-amide (sermorelin-type fragment) | 29 residues, native | No | Protease-labile at the N-terminus |
| CJC-1295 without DAC (modified GRF(1-29)) | 29 residues with D-Ala2, Gln8, Ala15 and a position-27 change | No | Short, pulse-like persistence per the V8 research guide |
| CJC-1295 with DAC | Tetrasubstituted hGRF(1-29) | Yes, maleimide on a C-terminal lysine | Detected in plasma beyond 72 h in rats (Jetté et al., 2005) |
What differs at the molecular level
The two forms share the receptor-binding chain and differ by a linker. The consequences are chemical and physical. The linker adds mass, adds a reactive group, and, once the maleimide has reacted with albumin, changes the molecule from a 29-mer peptide into a protein-peptide complex that is many times heavier. The reactive group also introduces thiol-reactive chemistry: the thiol-maleimide linkage is subject to retro-Michael exchange or stabilizing ring opening (Fontaine and colleagues, 2015), which is discussed in the conjugation literature. For identification purposes the practical differences are mass, hydrophobicity (and therefore chromatographic retention) and the presence or absence of a thiol-reactive group.
The product listed by V8 is the CJC-1295 (No DAC) form. Its product page states a molecular formula of C152H252N44O42, a 29-residue sequence with the substitution pattern reported on the certificate, ≥98% HPLC purity, 5 mg and 10 mg vials and storage at 2–8 °C, −20 °C for long term. Any listing that describes a DAC form should be accompanied by a different molecular formula that includes the linker.
Analytical checks that discriminate the forms
| Method | What it shows | What it cannot show |
|---|---|---|
| Intact mass by mass spectrometry | Whether the observed mass matches the declared sequence with or without the linker | Whether the linker is still reactive or has hydrolyzed, unless the hydrolysis mass shift is checked |
| Reversed-phase HPLC purity | Fraction of the main peak, and the presence of related impurities | Identity by itself; a peak is not a sequence |
| Amino acid or sequence analysis | Composition or sequence, including substitutions | Stereochemistry at a single residue unless chiral methods are used |
| Thiol-reactivity assay | Whether a maleimide is still present | Whether the peptide backbone is intact |
| Albumin-binding test (blot or shift assay) | Whether the compound forms an albumin complex, as in the original rat plasma Western blot (Jetté et al., 2005) | Quantitative binding stoichiometry without a calibrated method |
| Bioassay (cAMP or GH release) | Receptor activity of the preparation | Which form is present, since both are active |
A single method rarely settles identity. Intact mass is the most informative single check because the linker changes it by a predictable amount, but it should be combined with HPLC purity and, where the substitutions matter, sequence confirmation. The explanation of HPLC percentages and their limits is in understanding HPLC purity, and the layout of a certificate is in how to read a COA.
Nomenclature in the wider literature
Peptide names accumulate informal variants, and GH-axis names are a good example. The native hormone is called GHRH, GRF or GRH depending on the decade and the laboratory; the 1982 papers used "growth hormone-releasing factor", and the 1986 enzymology paper used "GRH" (Frohman and colleagues, 1986). Truncations are written with residue ranges in brackets, so GHRH(1-44), GHRH(1-29) and GHRH(3-44) are three different molecules, the last being the inactive product of N-terminal cleavage. Modified analogs add substitutions to the name or drop them entirely. A reader who sees "GRF(1-29)" cannot tell from the abbreviation alone whether the native or a substituted sequence is meant. The remedy is the same as for CJC-1295: look for the sequence in the paper or the certificate, and when a sequence is not given, regard the identity as unconfirmed.
The same caution applies to vendor listings, to forum posts and to summaries of papers. A statement like "CJC-1295 lasts several days" is true of one form and false of the other, and which one is meant is rarely stated. When quoting a result, include the form in the sentence, for example "the albumin-binding conjugate was detected in rat plasma beyond 72 hours", and give the citation. Doing so costs a few words and prevents a category error from spreading.
Reading a certificate for form identity
- Is the sequence written out? The three-letter or one-letter sequence with the D-amino acid and any non-standard residue marked, not just the name.
- Is the linker status stated? The words "with DAC" or "without DAC", or a molecular formula that includes or excludes the maleimide lysine.
- Is a measured mass reported and compared with a theoretical mass? Both values, with the method, so the difference can be seen.
- Is the HPLC purity linked to the lot? Lot number, test date and the chromatographic conditions where available.
- Is the supplied form stated? Lyophilized powder, vial size and storage.
Certificates for published lots are in the COA library. The comparison between the two forms is covered in the DAC versus no-DAC comparison, and the closely related fragment in sermorelin.
Why mislabeling would matter to a result
If a laboratory believes it is working with a long-persistence conjugate and in fact has the short-acting backbone, a null result in a schedule-dependent experiment would be misattributed. In the knockout mouse study, growth was normalized on a 24-hour interval and less so at 48 and 72 hours (Alba and colleagues, 2006); a short-acting backbone would not be expected to behave like the conjugate under those conditions. The reverse error, using a conjugate where a short pulse was intended, would blur the timing of a response, which matters because the GH response varies with the phase of the animal’s own rhythm (Tannenbaum and Ling, 1984). These are design consequences, not claims about any specific lot.
| Mistaken assumption | Consequence for the experiment |
|---|---|
| Vial is the albumin-binding form but is the backbone only | Persistence-dependent effects are absent, and the result is misread as lack of efficacy |
| Vial is the backbone but is the conjugate form | Sustained exposure blurs a pulse-timing experiment |
| Molar mass taken from the wrong form | Every stock concentration is wrong by a fixed factor |
| Medium contains thiols and the form carries a free maleimide | The linker may react with the medium before reaching its intended target |
One further point concerns reference materials. Where an experiment hinges on form identity, an authenticated reference standard analyzed in the same run as the test vial provides the strongest comparison, because retention time and mass are then compared on the same instrument and the same day.
A practical identity policy for a laboratory
Keep the certificate with the vial record. Write the form (with or without DAC) in the experiment notebook beside the lot number, and copy the molar mass used in calculations from the certificate or the product page, not from memory. If an experiment depends on the form, ask the supplier for an intact-mass result for the lot, and consider an independent check. When citing a paper, note which form it used, since the abbreviation alone does not say. These steps are inexpensive and prevent the type of silent error that is hardest to detect afterward. See also the purity testing article and the DAC purity testing article, and browse the catalog.
For laboratory research use only.
Frequently asked questions
Does CJC-1295 always mean the DAC form?
In the original 2005 paper the name referred to the designed molecule with the albumin-reactive linker. In many listings it can mean either form, so linker status must be stated.
What is the difference between with-DAC and no-DAC?
Both share a stabilized GRF(1-29) backbone. Only the DAC form carries a maleimide linker on a C-terminal lysine that binds albumin.
Is no-DAC the same as modified GRF(1-29)?
Yes. The V8 research guide uses the names CJC-1295 without DAC, modified GRF(1-29) and mod-GRF(1-29) for the same sequence.
Which analytical result best tells the forms apart?
Intact mass by mass spectrometry, because the linker shifts the mass by a predictable amount. It should be paired with HPLC purity.
Can HPLC purity confirm identity?
No. A single main peak does not prove sequence. Identity needs mass or sequence confirmation.
How was albumin binding shown originally?
A Western blot of rat plasma showed a CJC-1295 immunoreactive species at the albumin band from 15 minutes to beyond 24 hours.
What should a certificate state?
The sequence with substitutions, linker status or molecular formula, measured and theoretical mass, HPLC purity with lot number and test date, and supplied form.
What does the V8 product page list?
CJC-1295 (No DAC), C152H252N44O42, 5 mg and 10 mg vials, ≥98% HPLC purity, lyophilized powder, stored at 2–8 °C with −20 °C for long term.
Why does mislabeling matter?
A schedule-dependent result could be misattributed, and every stock concentration would be off by a fixed factor if the wrong molar mass were used.
Does V8 supply the DAC form?
No. The catalog lists the no-DAC form, and this article is an identity guide for laboratory readers.
Related reading: CJC-1295 Without DAC: Pulsatile GH-Axis Research, CJC-1295 Development History: From GHRH to DAC, CJC-1295 and IGF-1: What Animal Studies Measured.
References
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
- Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-913. doi:10.1172/JCI112679
- Fontaine SD, Reid R, Robinson L, Ashley GW, Santi DV. Long-term stabilization of maleimide-thiol conjugates. Bioconjug Chem. 2015;26(1):145-152. doi:10.1021/bc5005262
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
- Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology. 1984;115(5):1952-1957. doi:10.1210/endo-115-5-1952
